Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Alumis in a research report issued to clients and ...

Alumis (ALMS) and Kaken Pharmaceutical announced that the companies have entered into a collaboration and licensing agreement to develop, ...

Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.

Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical. The stock climbed 17.9% to $4.45 on Tuesday, recovering ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

Cas­sa­va Sci­ences fi­nal­ly stops work on Alzheimer’s drug: Af­ter a Phase 3 study of simu­fil­am failed in … Get free access to a limited number of articles, plus choose newsletters to get straight ...

Under the agreement terms, Alumis will receive $40 million in upfront and near-term co-development payments, with the possibility of an additional $140 million in milestone and field option payments.

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Alumis (NASDAQ:ALMS) stock surges 14% after the company reached a licensing deal with Kaken (KKPCF) for its skin disorder ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...